Zim Laboratories Ltd
Zim Laboratories Ltd (ZIMLAB) last reported results for the quarter ended Jun 2026, with sales of ₹94.18 crore and net profit of ₹-4.02 crore. The stock last traded at ₹138, a market capitalisation of ₹740 crore, on a P/E of 200. Over the past 52 weeks the stock has ranged between ₹59.3 and ₹145. Figures are as of 6 Oct 2026 and are not real time.
Zim Laboratories Ltd share price and key metrics
- Current price
- ₹138
- Market cap
- ₹740 cr
- Stock P/E
- 200
- Book value
- ₹55.4
- ROE
- 1.59%
- ROCE
- 4.76%
- Dividend yield
- 0.00%
- 52w high / low
- 145/59.3
Metrics as of 6 Oct 2026. Not real time.
Track Zim Laboratories Ltd
Cruxal reads every Zim Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Zim Laboratories Ltd growth and returns
- 10 Years
- 3%
- 5 Years
- 4%
- 3 Years
- -2%
- TTM
- 8%
- 10 Years
- -7%
- 5 Years
- -17%
- 3 Years
- -44%
- TTM
- -61%
- 10 Years
- %
- 5 Years
- 24%
- 3 Years
- 5%
- 1 Year
- 92%
- 10 Years
- 8%
- 5 Years
- 7%
- 3 Years
- 5%
- Last Year
- 2%
Zim Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹94.18 cr, up 31.2% from ₹71.76 cr a year earlier. Net profit was ₹-4.02 cr, down 115.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 92.14 | 96.33 | 109 | 71.76 | 88.71 | 109 | 105 | 94.18 |
| Expenses | 82.61 | 84.77 | 94.13 | 67.51 | 82.95 | 95.85 | 98.08 | 91.73 |
| Operating profit | 9.53 | 11.56 | 14.6 | 4.25 | 5.76 | 12.81 | 7.19 | 2.45 |
| OPM % | 10.34% | 12.00% | 13.43% | 5.92% | 6.49% | 11.79% | 6.83% | 2.60% |
| Other income | 1.32 | 1.75 | 1.71 | 1.48 | 2.04 | 1.7 | 6.16 | 0.99 |
| Interest | 2.89 | 2.73 | 2.91 | 3.3 | 3.16 | 3.43 | 3.31 | 3.64 |
| Depreciation | 5 | 4.88 | 5.29 | 4.86 | 4.98 | 5.03 | 5.1 | 5.37 |
| Profit before tax | 2.96 | 5.7 | 8.11 | -2.43 | -0.34 | 6.05 | 4.94 | -5.57 |
| Tax % | 19.59% | 30.00% | 39.70% | -22.63% | 23.53% | 27.27% | 24.29% | -28.01% |
| Net profit | 2.38 | 4 | 4.88 | -1.87 | -0.42 | 4.4 | 3.74 | -4.02 |
| EPS (₹) | 0.49 | 0.82 | 1.00 | -0.38 | -0.09 | 0.90 | 0.70 | -0.75 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Zim Laboratories Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 235 | 273 | 335 | 278 | 307 | 333 | 399 | 367 | 379 | 374 | 397 |
| Operating profit | 32 | 35 | 42 | 23 | 40 | 41 | 52 | 41 | 44 | 30 | 28 |
| OPM % | 13% | 13% | 13% | 8% | 13% | 12% | 13% | 11% | 12% | 8% | 7% |
| Net profit | 19 | 19 | 15 | 3 | 7 | 15 | 24 | 17 | 12 | 6 | 4 |
| EPS (₹) | — | — | 3.17 | 0.68 | 1.50 | 2.99 | 5.01 | 3.54 | 2.50 | 1.09 | 0.76 |
TTM is the trailing twelve months to the most recent quarter.
Zim Laboratories Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 8 | 8 | 16 | 16 | 16 | 16 | 49 | 49 | 49 | 54 |
| Reserves | 110 | 129 | 135 | 138 | 145 | 159 | 152 | 190 | 204 | 243 |
| Borrowings | 81 | 81 | 77 | 90 | 82 | 53 | 62 | 112 | 118 | 127 |
| Other liabilities | 60 | 81 | 100 | 82 | 82 | 112 | 79 | 96 | 102 | 116 |
| Total liabilities | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |
| Fixed assets | 89 | 94 | 106 | 116 | 107 | 106 | 109 | 161 | 164 | 162 |
| CWIP | 4 | 8 | 13 | 10 | 11 | 12 | 27 | 42 | 70 | 96 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other assets | 166 | 196 | 209 | 200 | 208 | 224 | 206 | 244 | 237 | 282 |
| Total assets | 259 | 298 | 328 | 325 | 325 | 342 | 342 | 447 | 472 | 539 |
As reported by the company. Total assets equal total liabilities by construction.
Zim Laboratories Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 32 | 37 | 35 | 22 | 32 | 49 | 38 | 16 | 41 | 50 |
| Cash from investing | -7 | -26 | -21 | -18 | -6 | -14 | -35 | -73 | -40 | -55 |
| Cash from financing | -25 | -10 | -15 | -3 | -26 | -33 | 1 | 60 | -9 | 28 |
| Net cash flow | -0 | 1 | -1 | 1 | -0 | 2 | 3 | 3 | -8 | 23 |
| Free cash flow | 24 | 8 | 15 | 3 | 25 | 34 | 1 | -57 | 1 | 11 |
| CFO / operating profit | 109% | 117% | 85% | 119% | 83% | 121% | 86% | 46% | 92% | 177% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Zim Laboratories Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 14% | 14% | 15% | 5% | 11% | 12% | 17% | 10% | 8% | 5% |
| Debtor days | 137 | 119 | 101 | 89 | 86 | 98 | 87 | 100 | 103 | 106 |
| Inventory days | 108 | 134 | 126 | 144 | 125 | 171 | 99 | 173 | 188 | 207 |
| Days payable | 137 | 172 | 165 | 168 | 149 | 185 | 107 | 133 | 151 | 161 |
| Cash conversion cycle | 108 | 81 | 63 | 65 | 62 | 85 | 79 | 140 | 140 | 152 |
| Working capital days | 54 | 37 | 39 | 46 | 49 | 67 | 67 | 57 | 60 | 41 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Zim Laboratories Ltd shareholding pattern
Promoters held 30.36% at Jun 2026, down from 33.26% at Jun 2025. FIIs 0.03% and DIIs 1.34%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 33.26% | 30.35% | 30.36% |
| FIIs | 0.00% | 0.21% | 0.01% | 0.03% | 0.00% | 0.02% | 0.00% | 0.03% |
| DIIs | 0.00% | 0.24% | 0.24% | 0.24% | 0.24% | 0.20% | 0.07% | 1.34% |
| Public | 66.73% | 66.29% | 66.49% | 66.46% | 66.52% | 66.52% | 69.57% | 68.28% |
| No. of shareholders | 17,716 | 17,450 | 17,448 | 16,641 | 17,282 | 17,251 | 16,636 | 14,510 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Zim Laboratories Ltd
Zim Laboratories Ltd corporate filings
- Zim Laboratories Limited updates credit rating reaffirmation with revised outlook from Stable to Negative by CARE Ratings, indicating potential credit risk concernsCompany Updatehigh impact
Cruxal's analysis: Zim Laboratories Limited has received a reaffirmation of its credit ratings from CARE…
Read the full analysis - Certificate under Regulation 74(5) of SEBI(DP) Regulations 2018 for the quarter ended 30th September,2026 is enclosed herewith .Company Updatelow impact
- Closure of Trading WindowInsider Trading / SASTlow impact
Cruxal's analysis: Please find enclosed the intimation regarding the closure of Trading Window
Read the full analysis - ZIM Laboratories incorporates wholly owned subsidiary in Chile to drive LATAM expansionCompany Updatemedium impact
Cruxal's analysis: ZIM Laboratories Limited has successfully incorporated a wholly owned subsidiary, 'ZIM…
Read the full analysis - ZIM Laboratories Limited completes capital infusion into step-down subsidiary ZIM Scientific Office LLCCompany Updatelow impact
Cruxal's analysis: ZIM Laboratories Limited has confirmed the completion of a total capital investment of 9…
Read the full analysis - Zim Laboratories Q1 FY27 Earnings Call: EU-GMP Remediation Nears Completion, Targeting 30-40% Growth in FY28Company Updatehigh impact
Cruxal's analysis: Zim Laboratories reported Q1 FY27 operating income of INR 94.2 crore, a 31.2% YoY growth…
Read the full analysis - ZIM Laboratories Limited shareholders approve revised remuneration for Managing Director and Whole-Time DirectorAGM/EGMlow impact
Cruxal's analysis: ZIM Laboratories Limited has successfully concluded a postal ballot process, with…
Read the full analysis - Zim Laboratories Limited releases audio recording of Q1 FY27 earnings conference callCompany Updatelow impact
Cruxal's analysis: Zim Laboratories Limited has formally disclosed the availability of the audio recording…
Read the full analysis - Zim Laboratories Limited reports consolidated net loss of 4.02 crore for Q1 FY2027Company Updatehigh impact
Cruxal's analysis: Zim Laboratories Limited reported a consolidated net loss of 4.02 crore for the quarter…
Read the full analysis - Zim Laboratories Limited Reports Q1 FY27 Financials: Revenue Growth Offset by Margin Compression and Net LossCompany Updatehigh impact
Cruxal's analysis: Zim Laboratories Limited reported Q1 FY27 total operating income of 94.2 crore…
Read the full analysis - ZIM Laboratories reports net loss of 4.02 crore for Q1 FY27 amid margin pressureBoard Meetinghigh impact
Cruxal's analysis: ZIM Laboratories Limited reported a consolidated net loss of 4.02 crore for the quarter…
Read the full analysis - ZIM Laboratories Schedules Q1FY27 Earnings Conference Call on August 7, 2026Company Updatelow impact
Cruxal's analysis: ZIM Laboratories Limited has announced an intimation for its Q1FY27 Earnings Conference…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.